That screenshot isn’t a study — it’s an AI Overview, not a peer-reviewed paper. And it doesn’t say tirzepatide is dosed at 30 mg in humans. It’s summarizing SURPASS data (which used up to 15 mg) and then speculating about kidney effects.
AI Overviews pull info from across the internet and often mash details together. It ’s mixing up “UACR ≥30 mg/g” (a kidney-damage threshold) with a 30 mg drug dose. SURPASS showed benefits on albuminuria in people with baseline UACR ≥30 mg/g, but the trials only tested up to 15 mg weekly (and single-dose SAD studies in humans went as high as ~8 mg). That’s not evidence for 25–60 mg/week or dosing every 3–4 days.
So, pretty sure the only thing that hit 30 mg in that screenshot was albuminuria, not tirzepatide. Google AI mixed up a kidney marker with a drug dose — which is why using AI summaries as a ‘credible study source’ is shaky from the start..... Just a quick reminder